Clobetasone


Concise Prescribing Info
Indications/Uses
Corticosteroid-responsive dermatoses.
Dosage/Direction for Use
Adult : Topical As 0.05% oint/cream: Apply thinly and rub gently onto the affected area once daily or bid. Max duration of therapy: 4 wk.
Dosage Details
Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: As 0.05% oint/cream: Apply thinly and rub gently onto the affected area once daily or bid, gradually discontinued once control is achieved. Max duration of therapy: 4 wk.
Child: Same as adult dose. Max duration of therapy: 7 days.
Contraindications
Untreated cutaneous infections, rosacea, acne vulgaris, perioral dermatitis, pruritus w/o inflammation.
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Contact dermatitis, skin irritation. Rarely, HPA axis suppression or hypercorticism (i.e. Cushing’s syndrome, hyperglycaemia, glycosuria).
CV: HTN.
Endocrine: Wt gain/obesity.
Musculoskeletal: Osteoporosis.
Ophthalmologic: Increased intraocular pressure, glaucoma, cataract.
Dermatologic: Exacerbation of eczema, skin atrophy, urticaria, rash, pruritus, erythema, acne, hypertrichosis, striae atrophicae, telangiectasia, mild depigmentation, perioral dermatitis.
Patient Counseling Information
Avoid contact w/ the face, eyes, scalp, genitals, groin, axilla, or between toes. Avoid use w/ occlusive dressing. Avoid abrupt withdrawal.
MonitoringParameters
Monitor for adrenal insufficiency and hypothalamic-pituitary-adrenal (HPA) axis suppression.
Drug Interactions
Increased systemic exposure w/ CYP3A4 enzyme inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplastic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasirox.
Action
Description: Clobetasone is a glucocorticoid w/ anti-inflammatory, antipruritic, and vasoconstrictive effects. It induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. histamine, kinins). Additionally, it decreases the density of mast cells, chemotaxis, and cytokine production.
Pharmacokinetics:
Absorption: May be systemically absorbed from intact healthy skin.
Metabolism: Metabolised in the liver.
Excretion: Via urine and faeces.
Chemical Structure

Chemical Structure Image
Clobetasone

Source: National Center for Biotechnology Information. PubChem Database. Clobetasone, CID=71387, https://pubchem.ncbi.nlm.nih.gov/compound/Clobetasone (accessed on Jan. 21, 2020)

Storage
Store between 15-25°C. Protect from light.
ATC Classification
D07AB01 - clobetasone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
References
Anon. Clobetasone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/03/2017.

Buckingham R (ed). Clobetasone Butyrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2017.

GlaxoSmithKline NZ Limited. Eumovate Cream 0.05% w/w data sheet 29 October 2012. Medsafe. http://www.medsafe.govt.nz/. Accessed 08/03/2017.

Joint Formulary Committee. Clobetasone Butyrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2017.

Disclaimer: This information is independently developed by MIMS based on Clobetasone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in